Marker Therapeutics, Inc.

Monthly Archives: January 2016

TapImmune Appoints Frederick G. Wasserman to its Board of Directors

…TapImmune Inc. (OTCMKTS: TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, is pleased to announce the appointment of Frederick G. Wasserman to its Board as an Independent Director.

Frederick (Rick) is an accomplished Board Director with 35 years of business experience.

Read More

TapImmune to Present at Biotech Showcase 2016 in San Francisco on January 11, 2016

…https://www.markertherapeutics.com/wp-content/uploads/2016/01/Biotech-Showcase-2016.png

JACKSONVILLE, FLORIDA, January 7 , 2015 / TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, will be a featured presenting company at Biotech Showcase 2016 to be held at the Parc 55, San Francisco Hilton, San Francisco, CA.

Read More